INTRODUCTION
Sarcoidosis is a multisystemic granulomatous disease of unknown origin. Cutaneous manifestations occur in approximately one quarter of sarcoid patients, and these lesions may present at the onset of the disease or following other systemic involvement [1] . The management of sarcoidosis remains a significant therapeutic challenge. Systemic and topical corticosteroids are popularly used treatment methods in cutaneous sarcoidosis but are a poor long-term management strategy given the range of side effects. Treatment with biologic agents has recently been proposed as another treatment option for cutaneous sarcoidosis [2] [3] [4] [5] . In the past decade, a number of case series has shown that infliximab is an effective and well-tolerated management strategy for this condition . The authors report three cases of cutaneous sarcoidosis that were refractory to standard therapy but responded to infliximab treatment. The authors also review the literature concerning the treatment of sarcoidosis with infliximab. hydroxychloroquine, and intralesional corticosteroids without improvement. As a result of a combination of lack of efficacy and intolerable side effects of these medications, the patient was switched to infliximab 5 mg/kg intravenously on weeks 0, 2, and 6, and then every 8 weeks in November 2008. After three infusions, the patient showed significant improvement of skin lesions, and prednisone was tapered back to 2.5 mg every other day. However, after 6 months of infusions, the patient began to experience some flaring of cutaneous lesions. Methotrexate 7.5 mg weekly was added in May 2009 in addition to infliximab in an effort to improve further the patient's cutaneous lesions. In addition, infliximab was increased to 5 mg/kg every 7 weeks, and shortly thereafter was increased again to 7.5 mg/kg every 7 weeks in November 2009 for flares near the time of infusion. The patient's cutaneous sarcoidosis was stable on this dose of methotrexate and infliximab for 9 months. In June 2011, the dosage again had to be increased to 10 mg/kg every 5 weeks due to flaring of lesions before infusions, which was able to control the disease better (Table 1) .
CASE REPORT

Case 2
A 53-year-old African American woman with a history of pulmonary sarcoidosis for 15 Thalidomide (100 mg/day) Fig. 1 The clinical manifestations of case 2 before initiating infliximab (Table 1) .
DISCUSSION
Sarcoidosis is a multisystemic non-caseating granulomatous disease of unknown origin that is driven by T-helper type 1 immune responses [27] . Cutaneous manifestations occur in 25-35% of cases and may present at the onset of the disease process [28] [29] [30] [31] . Diagnosis is usually made by clinical suspicion in conjunction with biopsy and the exclusion of other conditions [32] . The clinical history and prognosis of sarcoidosis is variable. In cutaneous sarcoidosis, there are no definite guidelines for systemic therapy, but progressive, widespread, and disfiguring lesions should certainly be treated [33] . Fig. 3 The clinical manifestation of case 3, 2 years after initiating infliximab Fig. 4 The clinical manifestations of case 3, 6 years after initiating infliximab
Systemic and topical corticosteroids remain the mainstay of treatment for various manifestations of sarcoidosis, including cutaneous sarcoidosis [33] . Unfortunately, the long-term side effects make corticosteroids a less than ideal long-term treatment option, and some patients remain refractory to this management strategy.
Tumor necrotic factor (TNF)-alpha is an important proinflammatory cytokine involved in the pathogenesis of sarcoidosis. Macrophages of sarcoidosis patients have been implicated as major releasers of TNF-alpha in sarcoidosis [34, 35] . Higher serum TNF-alpha levels have been shown not only in patients with slow onset sarcoidosis compared with acute onset, but levels have been shown to fluctuate in correlation with disease activity [36] [37] [38] . In addition, increased levels of TNF-alpha have been correlated with a greater risk of disease progression, relapse, and difficulty with treatment [36] . As a result of evidence of TNF-alpha involvement in the pathogenesis of sarcoidosis [39, 40] , alternative therapies for cutaneous sarcoidosis such as the TNF-alpha antagonists have been proposed [2, 3] . Reports on the efficacy of TNF antagonists used for cutaneous sarcoidosis are increasing, although at this time this treatment modality remains off label by the standards of the US Food and Drug Administration. Although there have been no comparative trials between the biologic agents for sarcoidosis, infliximab is the most heavily reported medication in the literature [6] [7] [8] [9] [10] [11] , and overall has shown great promise in the treatment of sarcoidosis patients refractory to more conventional therapies [6, 7, 12, 26] .
Favorable outcomes of infliximab therapy in patients who have renal sarcoidosis [13] , vertebral sarcoidosis [14] , joint sarcoidosis [15] , optic neuropathy [16] , pulmonary sarcoidosis [6, 17] , retinal vasculitis [18] , cutaneous sarcoidosis [3] [4] [5] 22] , neurosarcoidosis [19] , and cardiac sarcoidosis [20] have also been reported.
For sarcoidosis patients reported in the literature, the usual dose of infliximab has been 3-10 mg/kg per dose at 0, 2, and 6 weeks, followed by every 8 weeks for maintenance [25, 34] . If patients respond insufficiently to 5 mg/kg, reducing the treatment interval has been shown to lead to higher trough levels than increasing the dose [25] . A randomized, doubleblind, placebo controlled study on the efficacy of infliximab in 36 sarcoidosis patients with cutaneous and pulmonary involvement used a 6-week maintenance regimen. After 24 weeks of treatment, patients overall showed improvement in cutaneous findings compared with placebo, although this was not statistically significant (P = 0.09) [12] . In addition, a retrospective review of lupus pernio (13 courses of treatment with infliximab in nine patients) reported the success of a 6-week maintenance regimen, which was statistically more efficacious than corticosteroids used with and without other non-steroid immunosuppressive agents (P = 0.0015) [5] . All three patients in the current case study were able to control their cutaneous sarcoidosis, although doses had to be tailored to the severity and variably refractory nature of their diseases. However, it should be noted by the prescribing physician that increased doses of immunosuppression can of course lead to an increased tendency toward infection, and can also be associated with demyelination and worsening of multiple sclerosis lesions [41] . Increasing doses of infliximab should not be given lightly.
While TNF inhibitors have been shown to be of benefit in treating sarcoidosis, it is of some interest that a few cases have been reported wherein patients developed sarcoidosis while undergoing treatment with anti-TNF therapy.
In the largest reported series of sarcoid-like granulomas developing during TNF inhibitor therapy [42] , three of 10 patients treated with infliximab for ankylosing spondylitis developed pulmonary sarcoidosis 14-51 months after the initiation of treatment. All three patients improved within 6 months of discontinuation [42] . Other case reports of infliximab-treated patients include one patient with ankylosing spondylitis who developed pulmonary sarcoidosis after 5 years of therapy [43] , and patients with psoriatic arthritis who developed pulmonary sarcoidosis [44] and cutaneous sarcoidosis [45] . The mechanisms of sarcoidosis development during anti-TNF-alpha therapy are unclear.
In an article by Saleh et al. [21] , the following were offered as indications to initiate treatment with infliximab for refractory sarcoidosis:
• unsuccessful treatment with systemic corticosteroids;
• intolerant to systemic steroids side effects;
• unsuccessful treatment or intolerance to other systemic therapies;
• requirement for additional systemic therapy but intolerant to alternative agents.
CONCLUSION
In summary, the authors report three cases of patients with refractory sarcoidosis successfully treated with infliximab. Their clinical outcomes were good, sustained, and there was no associated morbidity from the medication. 
